Differences in Drug Resistance in Lung Cancer Types
Author Information
Author(s): J Kreisholt, M Sorensen, PB Jensen, BS Nielsen, CB Andersen, M Sehested
Primary Institution: Rigshospitalet, Copenhagen, Denmark
Hypothesis
The study aims to investigate the expression of topoisomerase II alpha, P-glycoprotein, and multidrug resistance protein in small-cell and non-small-cell lung cancer.
Conclusion
The study found that non-small-cell lung cancer has significantly lower levels of topoisomerase II alpha compared to small-cell lung cancer, which may explain the differences in their responses to treatment.
Supporting Evidence
- Non-small-cell lung cancer had significantly less topoisomerase II alpha than small-cell lung cancer.
- Only 5 out of 27 non-small-cell lung cancer cases had more than 5% positive cells for topoisomerase II alpha.
- After treatment, there was an increase in P-glycoprotein and multidrug resistance protein positivity in small-cell lung cancer.
Takeaway
This study looked at two types of lung cancer and found that one type is much less responsive to certain drugs because it has less of a key protein that those drugs target.
Methodology
Immunohistochemical analysis was performed on paraffin-embedded tissue from 27 cases of untreated non-small-cell lung cancer and 29 cases of untreated small-cell lung cancer.
Limitations
The study included a small sample size and was retrospective in nature.
Participant Demographics
The SCLC patients had a mean age of 57 years with an equal male-female ratio.
Statistical Information
P-Value
p<0.0001
Statistical Significance
p<0.0001
Want to read the original?
Access the complete publication on the publisher's website